IP Library Granted Patent US 11,993,645
Granted Patent B2
US 11,993,645 · App. 16/476,501 · Granted May 28, 2024

Compositions comprising R-Spondin (RSPO) surrogate molecules

Inventors: Vincent Christopher Luca (Menlo Park, CA); Kenan Christopher Garcia (Menlo Park, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C07K16/18C07K14/5406C07K14/55A61K38/00C07K2317/622C07K2317/77C07K2319/21C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,993,645
App. No.
16/476,501
Granted
May 28, 2024
Kind
B2
Abstract

R-spondin (RSPO) surrogate compositions and methods for their use are provided. RSPO surrogates of the invention comprise (i) a specific binding domain for Ring Finger Protein 43 (RNF43) or Zinc and Ring Finger Protein 3 (ZNRF3) and (ii) a cell targeting domain More specifically, wherein the specific binding domain for RNF43 or ZNRF3 is an antibody fragment, and wherein the cell targeting domain is a cytokine.

Claims (12)

1. An RSPO surrogate composition that comprises:

(i) a specific binding domain for RNF43 or ZNRF3, wherein the specific binding domain for RNF43 or ZNRF3 is an antibody or antigen-binding fragment thereof; and

(ii) a cell-targeting domain, wherein the cell-targeting domain is a cytokine or growth factor that specifically binds a cell surface receptor.

2. The composition of claim 1 , wherein the specific binding domain for RNF43 or ZNRF3 comprises 6 CDR sequences of Z6 or R5 binding sequences set forth in any one of SEQ ID NO:1-4.

3. The composition of claim 1 , wherein the specific binding domain for RNF43 or ZNRF3 is a single-chain Fv (scFv) construct.

4. The composition of claim 1 , wherein the cell-targeting domain is the or growth factor.

5. The composition of claim 4 , wherein the cell-targeting domain is the cytokine.

6. The composition of claim 5 , wherein the cytokine is IL-2 or IL-4.

7. The composition of claim 1 , wherein the domains are fused through a flexible linker.

8. The composition of claim 1 , wherein the domains are directly joined.

9. The composition of claim 1 , formulated with an effective dose of a Wnt agent.

10. The composition of claim 1 , joined to a Wnt agent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: LUCA, VINCENT CHRISTOPHER
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 053421/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: GARCIA, K. CHRISTOPHER
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 053421/0941 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: HOWARD HUGHES MEDICAL INSTITUTE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 053422/0011 →
Continuity (2)
Provisional Application 62444987 · Jan 11, 2017
Related Publication 20200024338A1 · Jan 23, 2020
Cited By (1)
US 12,466,884